EVOTEC SE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.45 EUR | +1.82% |
|
+1.13% | -36.80% |
| Apr. 18 | Evotec, Variant Bio Team Up to Develop Treatment for Fibrosis | MT |
| Apr. 18 | Evotec, Variant Bio Launch Partnership to Develop Treatments for Fibrosis | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- Low profitability weakens the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -36.80% | 2.49B | A- | ||
| -1.82% | 41.36B | B | ||
| +44.25% | 41.3B | A | ||
| +2.56% | 39.61B | B- | ||
| -12.11% | 25.62B | C | ||
| +3.09% | 24.09B | B- | ||
| -24.16% | 18.38B | B | ||
| +22.12% | 11.85B | C+ | ||
| -3.74% | 11.82B | C+ | ||
| +7.75% | 11.07B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- EVT Stock
- Ratings Evotec SE
